{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/restless-legs-syndrome/management/management/","result":{"pageContext":{"chapter":{"id":"33ccae89-80e7-572a-b148-a81c781d0956","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field eddf2dba-cfa9-46c0-96fa-b9f2d737a943 --><h2>Scenario: Management of restless legs syndrome</h2><!-- end field eddf2dba-cfa9-46c0-96fa-b9f2d737a943 -->","summary":"Covers the management of people with restless legs syndrome.","htmlStringContent":"<!-- begin item 154db9d9-8ed1-46d4-af73-24b1fc13634c --><!-- begin field 040fe6bf-b48b-4c4a-8dd7-acbc0155c170 --><p>From age 18 years onwards.</p><!-- end field 040fe6bf-b48b-4c4a-8dd7-acbc0155c170 --><!-- end item 154db9d9-8ed1-46d4-af73-24b1fc13634c -->","topic":{"id":"ce2c49b0-9c88-5bbe-b742-179c3a41de7d","topicId":"8560b6b4-74c4-48fb-99b2-1738f7bdfc1c","topicName":"Restless legs syndrome","slug":"restless-legs-syndrome","lastRevised":"Last revised in November 2020","chapters":[{"id":"0c5685ed-e78f-5c68-8983-83a722c74100","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e6a7ab99-3bce-5334-8352-694d31ef5cc0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"461085e4-b723-57af-8f1a-16da6b5276cd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8a4d8c25-f2fc-5706-989b-f6210f6e1fb8","slug":"changes","fullItemName":"Changes"},{"id":"08d30779-72aa-5609-89bb-35fa111203a1","slug":"update","fullItemName":"Update"}]},{"id":"8544bde0-46f9-502a-aec7-2a5a2d449009","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c04c9edd-95d7-5e3f-94ea-5c7ecd6205a8","slug":"goals","fullItemName":"Goals"},{"id":"4d33d470-bfd2-518f-aebb-b9e86daa02ab","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ab4dd298-08f9-5497-81cd-0ab7e978b675","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8d907e60-5b96-5b39-a188-b481acc2935a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"330f64fa-36dd-5bd9-847c-b379cdd7b437","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"9a4d2e02-acae-5411-92f3-bca31ce98b25","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"877ed575-950a-5933-ae1f-abcee48927b8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"623e0c19-8a9e-5892-b3f3-a72ab9d617ce","slug":"definition","fullItemName":"Definition"},{"id":"f6fe6742-330a-5aea-8b52-b32fc2b3ab48","slug":"causes","fullItemName":"Causes"},{"id":"7a8e05a8-1db9-5aac-9b56-c5be8e7eb9d6","slug":"prevalence","fullItemName":"Prevalence"},{"id":"86293e20-8427-58da-8512-93f22162d764","slug":"prognosis","fullItemName":"Prognosis"},{"id":"043ee2a1-37c5-5b2f-8d10-0a9d2d41abe0","slug":"complications","fullItemName":"Complications"}]},{"id":"0ef4212f-c56f-508b-897c-741bceff55bb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6836b996-4eee-5e2a-a99b-84973696e8e3","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"5ccc9458-1b9d-5fa7-a565-2b00a539b9bd","slug":"assessment","fullItemName":"Assessment"},{"id":"729e434c-5849-59fb-b3ca-e7a86f26a8d6","slug":"investigations","fullItemName":"Investigations"},{"id":"0ce4b1b3-2e3a-5901-8e9c-981cea4198d7","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7a12e175-49ce-5c68-9c8f-756159646a3f","fullItemName":"Management","slug":"management","subChapters":[{"id":"33ccae89-80e7-572a-b148-a81c781d0956","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"9b2fd470-be46-5a93-9f1a-502f0a8434dc","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ae3af6c6-eb78-5674-a94f-f5f087e5f812","slug":"pramipexole","fullItemName":"Pramipexole"},{"id":"1664194f-800a-54c6-bd79-106678653aaa","slug":"ropinirole","fullItemName":"Ropinirole"},{"id":"1a0b2fc3-18c3-51a9-968c-88bb51f2637f","slug":"rotigotine","fullItemName":"Rotigotine"},{"id":"87f55f71-dd3d-5e97-9c88-5fe3a78503db","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"a931371b-564c-5833-b5b4-d21ad3f1a361","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"6590cad9-132e-548c-b7ad-bf4375ef2caf","slug":"codeine","fullItemName":"Codeine"},{"id":"70676cc9-d1a4-5639-a227-62e452e13b2b","slug":"benzodiazepines-z-drugs","fullItemName":"Benzodiazepines and Z-drugs"},{"id":"fe9dc2de-9fbe-527f-b34b-446254f3d127","slug":"augmentation","fullItemName":"Augmentation"},{"id":"2203998a-e9f3-59c3-9132-50418bf47566","slug":"loss-of-efficacy","fullItemName":"Loss of efficacy"},{"id":"7d279d8d-8d6c-5c7d-8597-6ee343a7a574","slug":"impulse-control-disorders","fullItemName":"Impulse control disorders"}]},{"id":"0fadb6b8-91c2-57be-8c1d-2d3e31da6d60","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"afa91ee5-1f42-5cc6-b9ec-6ef16749457d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"baf472ab-f0f9-518a-8310-81583fd7d905","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"9d31c719-7426-52cb-8343-b11a7bb8b5b3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a915b18c-93a0-5269-8ff1-021677ba9dd3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6e85726f-b5ea-5c2c-a886-f74ab46fbc6b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8ac2285b-b086-5b54-98d6-0ec8c43f05c2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8a058ec2-b2e0-5618-b51f-27102b964d76","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7a12e175-49ce-5c68-9c8f-756159646a3f","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"9b3f0b25-4f2e-50cf-912c-cd8cdeb4caa6","slug":"overview","fullItemName":"Overview","depth":3,"htmlHeader":"<!-- begin field dbbdd8e3-b2da-4060-884d-db8f34a59cc9 --><h3>What are the principles of managing restless legs syndrome?</h3><!-- end field dbbdd8e3-b2da-4060-884d-db8f34a59cc9 -->","summary":null,"htmlStringContent":"<!-- begin item db555afe-daf8-461d-9109-a376180aead1 --><!-- begin field f7883106-649c-4361-b0d9-3a0346a7ac3c --><ul><li><strong>Address any underlying <a class=\"topic-reference internal-reference\" href=\"/topics/restless-legs-syndrome/background-information/causes/\">cause</a> that may have precipitated or exacerbated restless legs syndrome (RLS).</strong> <strong>For example:</strong><ul><li>Iron deficiency anaemia, or serum ferritin less than 50 to 75 micrograms/L — investigate to identify a cause of iron deficiency and prescribe iron supplements (if appropriate).<ul><li>For more information see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/anaemia-iron-deficiency/\">Anaemia - iron deficiency</a>.</li></ul></li><li>An existing drug that may be precipitating or exacerbating symptoms — consider if changing or stopping it is an option.</li><li>Pregnancy: reassure that symptoms are likely to resolve or improve soon after delivery — drug treatment is not recommended during pregnancy or breastfeeding.</li></ul></li><li><strong>Offer self-help advice to all people with RLS. </strong>Consider including:<ul><li>Measures to prevent or reduce the severity of RLS:<ul><li>Good sleep hygiene (see the section on <a class=\"topic-reference external-reference\" href=\"/topics/insomnia/management/managing-short-term-insomnia-less-3-months/#good-sleep-hygiene\">Good sleep hygiene</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/insomnia/\">Insomnia</a>).</li><li>Reducing caffeine and alcohol consumption, if applicable.</li><li>Stopping smoking (if relevant).</li><li>Undertaking moderate regular exercise.</li></ul></li><li>Measures to relieve an episode of RLS:<ul><li>Walking and stretching the affected limbs.</li><li>Application of heat with heat pads or a hot bath.</li><li>Relaxation exercises.</li><li>Mental alertness distraction at times of rest (for example, games or reading).</li><li>Massaging affected limbs.</li></ul></li></ul></li><li><strong>Offer patient information, such as the leaflet on <a href=\"https://www.nhs.uk/conditions/restless-legs-syndrome/\" data-hyperlink-id=\"f16a5b9b-e3c7-4fc9-9751-ac0e009e384e\">RLS</a> published by the NHS.</strong></li><li><strong>Consider treatment options for people with idiopathic RLS </strong>taking into account the <a class=\"topic-reference internal-reference\" href=\"/topics/restless-legs-syndrome/diagnosis/assessment/\">impact of symptoms</a> on the person's quality of life.<ul><li>For people with mild symptoms, explanation, reassurance, and self-help measures may be sufficient.</li></ul></li><li>For people with moderate or severe symptoms, consider <a class=\"topic-reference internal-reference\" href=\"/topics/restless-legs-syndrome/management/management/#drug-treatment\">drug treatment</a>.</li></ul><!-- end field f7883106-649c-4361-b0d9-3a0346a7ac3c --><!-- end item db555afe-daf8-461d-9109-a376180aead1 -->","subChapters":[{"id":"55d55d9b-c642-5e31-baf4-c6434c5bfbdf","slug":"basis-for-recommendation-aa9","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 71409887-1fcb-464d-84e5-df5e0904a85f --><h4>Basis for recommendation</h4><!-- end field 71409887-1fcb-464d-84e5-df5e0904a85f -->","summary":null,"htmlStringContent":"<!-- begin item aa9146ed-c496-4ea6-ad52-990fab51eb90 --><!-- begin field 3a1615f1-a1b2-470b-a0d7-89b06a3c100b --><h5>Addressing underlying causes</h5><ul><li>The recommendation to give iron replacement therapy to all people with low serum ferritin levels, even in the absence of overt anaemia, is based on expert opinion in <em>Algorithms for the diagnosis and treatment of restless legs syndrome in primary care </em>produced by a task force for the European Restless Legs Syndrome Study Group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2011</a>], and on expert opinion in narrative reviews [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Leschziner, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Nagandla, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2017</a>].<ul><li>Ferritin levels less than 50 micrograms/L have been correlated with increased symptom severity in people with restless legs syndrome (RLS) and a greater reduction in their quality of sleep [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Earley, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Silber, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Gamaldo, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Oertel, 2007</a>]. The 2011 document <em>Algorithms for the diagnosis and treatment of restless legs syndrome in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2011</a>] therefore recommended a ferritin level of 50 micrograms/L as the cut off at which treatment was indicated. </li><li>The more recent <em>Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children</em> from the International Restless Leg Syndrome Study Group (IRLSSG) recommends ferritin level cut-off of 75 micrograms/L for iron replacement therapy. This is based on research showing that administration of oral iron when serum ferritin is greater than 75 micrograms/L is likely to have only limited benefits, as well as the findings of one small study that provides 'Level C evidence' (suggesting that the treatment is 'possibly effective') showing oral ferrous sulfate 325 mg (65 mg elemental iron) and vitamin C 100 mg twice daily were more effective than placebo for patients with serum ferritins between 15 and 75 micrograms/L [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Allen, 2018</a>].</li><li>CKS therefore recommends that a serum ferritin cut-off of 50 to 75 micrograms/L be employed. This is supported by expert opinion in the <em>Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2016</a>].</li></ul></li><li>The recommendation to consider existing drugs as a cause is based on expert opinion in narrative reviews [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Leschziner, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Nagandla, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2017</a>].</li><li>The recommendation not to use drug treatment during pregnancy is based on <em>The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2013</a>] that states that \"in general, pharmacologic treatment should be avoided for RLS symptoms occurring during pregnancy ... Consideration should be given to fully replenishing iron stores prior to pregnancy and maximizing nonpharmacologic treatments\".</li></ul><h5>Self-help advice</h5><p>The recommendations on self-help advice are based on expert opinion in <em>Algorithms for the diagnosis and treatment of restless legs syndrome in primary care </em>produced by a task force for the European Restless Legs Syndrome Study Group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2011</a>] and on expert opinion in narrative reviews [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Leschziner, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Nagandla, 2013</a>].</p><h5>Treatment options for idiopathic RLS</h5><ul><li>The recommendation to consider drug treatment for people with moderate or severe RLS is based on expert opinion in <em>Algorithms for the diagnosis and treatment of restless legs syndrome in primary care </em>produced by a task force for the European Restless Legs Syndrome Study Group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2011</a>].</li></ul><!-- end field 3a1615f1-a1b2-470b-a0d7-89b06a3c100b --><!-- end item aa9146ed-c496-4ea6-ad52-990fab51eb90 -->","subChapters":[]}]},{"id":"0b5b4d9c-07b9-592e-ae8d-df2df89e2323","slug":"drug-treatment","fullItemName":"Drug treatment","depth":3,"htmlHeader":"<!-- begin field 1b895cd2-b195-44ec-befe-c578ed707044 --><h3>What drugs should I consider to treat restless legs syndrome?</h3><!-- end field 1b895cd2-b195-44ec-befe-c578ed707044 -->","summary":null,"htmlStringContent":"<!-- begin item e01be7d9-5e3f-480f-afe0-404e526bf43c --><!-- begin field 00cd399b-b702-404d-b0eb-81cae4c27b8d --><ul><li><strong>First-line recommended drug options for people with frequent or daily symptoms </strong>are either:<ul><li>A non-ergot dopamine agonist (<a class=\"topic-reference internal-reference\" href=\"/topics/restless-legs-syndrome/prescribing-information/pramipexole/\">pramipexole</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/restless-legs-syndrome/prescribing-information/ropinirole/\">ropinirole</a>, or <a class=\"topic-reference internal-reference\" href=\"/topics/restless-legs-syndrome/prescribing-information/rotigotine/\">rotigotine</a>), <em>or</em></li><li>An alpha-2-delta ligand (<a class=\"topic-reference internal-reference\" href=\"/topics/restless-legs-syndrome/prescribing-information/pregabalin/\">pregabalin</a> or <a class=\"topic-reference internal-reference\" href=\"/topics/restless-legs-syndrome/prescribing-information/gabapentin/\">gabapentin</a> — both off-label indications).</li></ul></li><li><strong>Before commencing drug treatment, ensure the person is aware:</strong><ul><li>Of possible treatment complications relating to dopamine agonists. In particular, <a class=\"topic-reference internal-reference\" href=\"/topics/restless-legs-syndrome/prescribing-information/augmentation/\">augmentation</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/restless-legs-syndrome/prescribing-information/loss-of-efficacy/\">loss of efficacy</a>, and the risk of <a class=\"topic-reference internal-reference\" href=\"/topics/restless-legs-syndrome/prescribing-information/impulse-control-disorders/\">impulse control disorders</a> (ICDs).</li><li>That if a dopamine agonist is taken, the person (and, ideally a carer or close family member) should be warned about the possibility of an ICD developing. Symptoms of an ICD should be sought on each review consultation.</li><li>That treatment for idiopathic RLS aims to control symptoms, and is likely to be lifelong. However, it is reasonable to have short drug holidays every year to see if a remission or easing of symptoms has occurred.</li></ul></li><li><strong>Drug dosages should be kept to the minimum required to ease symptoms </strong>as the higher the dose, the greater the risk of augmentation.</li><li><strong>Factors that may influence the preferred choice of drug include:</strong><ul><li>A dopamine-receptor agonist is generally preferred for people with severe symptoms, who are obese, have comorbid depression, are at increased risk of falls, or have cognitive impairment.</li><li>An alpha-2-delta ligand is generally preferred for people with severe sleep disturbance (disproportionate to other RLS symptoms), comorbid insomnia or anxiety, RLS-related or comorbid pain, or a history of an ICD.</li><li>As alpha-2-delta ligands pose little or no risk of <a class=\"topic-reference internal-reference\" href=\"/topics/restless-legs-syndrome/prescribing-information/augmentation/\">augmentation</a>, if clinically appropriate, they may be preferred first-line where the physician is inexperienced in long-term management of RLS.</li><li>Consider rotigotine transdermal patch if the person has significant daytime symptoms as it has a long duration of action.</li></ul></li><li><strong>A weak opioid (such as codeine), taken intermittently or regularly (depending on symptoms), is an alternative,</strong> particularly for people with painful symptoms of RLS. However, take into account the risk of opioid dependence.</li><li><strong>For people with significant sleep disturbance, consider a short course of, or intermittent use of, a hypnotic </strong>(benzodiazepine or Z-drug). For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/insomnia/\">Insomnia</a>.</li></ul><!-- end field 00cd399b-b702-404d-b0eb-81cae4c27b8d --><!-- end item e01be7d9-5e3f-480f-afe0-404e526bf43c -->","subChapters":[{"id":"fba59e2a-88e5-5d98-b278-b611cd7d546f","slug":"basis-for-recommendation-627","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 167d882b-1dc9-4a44-9615-9accc55155c8 --><h4>Basis for recommendation</h4><!-- end field 167d882b-1dc9-4a44-9615-9accc55155c8 -->","summary":null,"htmlStringContent":"<!-- begin item 627d1f41-b32f-404d-b407-91d319527d9a --><!-- begin field 58541587-2f63-4293-94e5-285c4781fa5e --><p>The recommendations relating to drug treatment options are based on expert opinion in the <em>European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2012a</a>], <em>The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2013</a>], and <em>Guidelines for the first-line treatment of restless legs syndrome/Willis–Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2016</a>].</p><!-- end field 58541587-2f63-4293-94e5-285c4781fa5e --><!-- end item 627d1f41-b32f-404d-b407-91d319527d9a -->","subChapters":[]}]},{"id":"37dc3f50-6d97-5a1b-a988-57698244da7d","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field 391632b2-9f1f-4704-b834-0ba093423774 --><h3>When should I refer someone with restless legs syndrome?</h3><!-- end field 391632b2-9f1f-4704-b834-0ba093423774 -->","summary":null,"htmlStringContent":"<!-- begin item 696c0bb2-f8c1-457c-a6ab-85cf468fc71e --><!-- begin field 9622bf1d-9e9f-4d41-b254-f9ea717bce91 --><ul><li>Consider referral to a specialist (either a sleep specialist or a neurologist) if there is doubt about the diagnosis or if treatment is unsuccessful. The European Restless Legs Syndrome Study Group task force defines unsuccessful treatment as:<ul><li>An insufficient initial response despite an adequate dose and duration of treatment.</li><li>The response to treatment becomes insufficient after a time despite an increased dose.</li><li>There are intolerable adverse effects.</li><li>The person reaches the maximum recommended dosage and treatment ceases to be effective.</li><li>Symptoms suggestive of augmentation become apparent.</li></ul></li></ul><!-- end field 9622bf1d-9e9f-4d41-b254-f9ea717bce91 --><!-- end item 696c0bb2-f8c1-457c-a6ab-85cf468fc71e -->","subChapters":[{"id":"810373cc-54cf-59ae-bcb1-2c1bdd6e474a","slug":"basis-for-recommendation-2a3","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a6a4409b-7e80-48a0-8ce4-960002357e74 --><h4>Basis for recommendation</h4><!-- end field a6a4409b-7e80-48a0-8ce4-960002357e74 -->","summary":null,"htmlStringContent":"<!-- begin item 2a326a89-1d69-4396-8911-3a6d90371534 --><!-- begin field 6d4bbf94-20ec-4b70-ba90-b63d94daa431 --><p>The recommendations relating to referral of people with restless legs syndrome are based on expert opinion in <em>Algorithms for the diagnosis and treatment of restless legs syndrome in primary care </em>produced by a task force for the European Restless Legs Syndrome Study Group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2011</a>].</p><!-- end field 6d4bbf94-20ec-4b70-ba90-b63d94daa431 --><!-- end item 2a326a89-1d69-4396-8911-3a6d90371534 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}